|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1997-3-25
|
|
pubmed:abstractText |
In a European, prospective, 1:2 randomized phase II multicentre study, 237 patients with advanced or metastatic prostate cancer were treated with either the 1M- (80 patients) or 3M-depot formulation (157 patients) of leuprorelin acetate for 9 months to compare efficacy and safety.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0302-2838
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7-14; discussion 19-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8977984-Aged,
pubmed-meshheading:8977984-Antineoplastic Agents, Hormonal,
pubmed-meshheading:8977984-Delayed-Action Preparations,
pubmed-meshheading:8977984-Gonadotropins,
pubmed-meshheading:8977984-Humans,
pubmed-meshheading:8977984-Leuprolide,
pubmed-meshheading:8977984-Male,
pubmed-meshheading:8977984-Prostate-Specific Antigen,
pubmed-meshheading:8977984-Prostatic Neoplasms,
pubmed-meshheading:8977984-Testosterone,
pubmed-meshheading:8977984-Time Factors
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
|
|
pubmed:affiliation |
Urological Clinic, University of Tübingen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
